Previous Close | 15.21 |
Open | 15.33 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 15.18 - 15.35 |
52 Week Range | 14.21 - 18.18 |
Volume | |
Avg. Volume | 95,561 |
Market Cap | 28.7B |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | 27.37 |
EPS (TTM) | 0.56 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.41 (2.66%) |
Ex-Dividend Date | Mar 29, 2022 |
1y Target Est | 17.97 |
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022.
Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.
Earlier today, Seagen Inc (NASDAQ: FBI) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in metastatic urothelial carcinoma (mUC). Needham says that the results from Cohort K primarily live up to expectations. The management has previously indicated that results from Cohort K could be used to support accelerated approval in the 1L cis-ineligible mUC setting. See the Seagen Analyst Page here.